Foreword

The evolution of breast cancer from an early stage to metastatic disease is highly complex and is associated with greater heterogeneity, altered gene expression, emergence of new mutations, increased cell proliferation and, eventually, development of resistance to treatment. Collectively, these fact...

Full description

Saved in:
Bibliographic Details
Published inFuture oncology (London, England) Vol. 14; no. 7; p. 1
Main Authors Ana Lluch Hernández, Cristina Hernando Meliá
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.03.2018
Subjects
Breast cancer
Cancer therapies
Cell cycle
Chemotherapy
Gene expression
Medical prognosis
Metastasis
Patients
Studies
Tumors
Womens health
United States > US
Online AccessGet full text

Cover

More Information
Summary:The evolution of breast cancer from an early stage to metastatic disease is highly complex and is associated with greater heterogeneity, altered gene expression, emergence of new mutations, increased cell proliferation and, eventually, development of resistance to treatment. Collectively, these factors make implementation of clinical management and therapeutic strategies in MBC patients a formidable challenge. [...]in the absence of sufficient data to provide guidance in this context, we continue to rely on traditional clinical parameters when deciding an optimal treatment approach. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Efficacy of eribulin in patients with metastatic breast cancer: a pooled analysis by HER2 and ER status. 50th Annual Meeting of the American Society of Clinical Oncology.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2018-0094